The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension
Abstract
To determine the effects of continuation versus discontinuation of alendronate on BMD and markers of bone turnover, we conducted an extension trial in which 1099 older women who received alendronate in the FIT were re-randomized to alendronate or placebo. Compared with women who stopped alendronate, those continuing alendronate for 3 years maintained a higher BMD and greater reduction of bone turnover, showing benefit of continued treatment. However, among women who discontinued alendronate and took placebo in the extension, BMD remained higher, and reduction in bone turnover was greater than values at FIT baseline, showing persistence of alendronate's effects on bone. Introduction: Prior trials including the Fracture Intervention Trial (FIT) have found that therapy with alendronate increases BMD and decreases fracture risk for up to 4 years in postmenopausal women with low BMD. However, it is uncertain whether further therapy with alendronate results in preservation or further gains in BMD and if skeletal effects of alendronate continue after treatment is stopped. Materials and Methods: We conducted a follow-up placebo-controlled extension trial to FIT (FIT long-term extension [FLEX]) in which 1099 women 60-86 years of age who were assigned to alendronate in FIT with an average duration of use of 5 years were re-randomized for an additional 5 years to alendronate or placebo. The results of a preplanned interim analysis at 3 years are reported herein. Participants were re-randomized to alendronate 10 mg/day (30%), alendronate 5 mg/day (30%), or placebo (40%). All participants were encouraged to take a calcium (500 mg/day) and vitamin D (250 IU/day) supplement. The primary outcome was change in total hip BMD. Secondary endpoints included change in lumbar spine BMD and change in markers of bone turnover (bone-specific alkaline phosphatase and urinary type I collagen cross-linked N-telopeptide). Results: Among the women who had prior alendronate therapy in FIT, further therapy with alendronate (5 and 10 mg groups combined) for 3 years compared with placebo maintained BMD at the hip (2.0% difference; 95% CI, 1.6-2.5%) and further increased BMD at the spine (2.5% difference; 95% CI, 1.9-3. 1%). Markers of bone turnover increased among women discontinuing alendronate, whereas they remained stable in women continuing alendronate. Cumulative increases in BMD at the hip and spine and reductions in bone turnover from 8.6 years earlier at FIT baseline were greater for women continuing alendronate compared with those discontinuing alendronate. However, among women discontinuing alendronate and taking placebo in the extension, BMD remained higher and reduction in bone turnover was greater than values at FIT baseline. Conclusions: Compared with women who stopped alendronate after an average of 5 years, those continuing alendronate maintained a higher BMD and greater reduction of bone turnover, showing benefit of continued alendronate treatment on BMD and bone turnover. On discontinuation of alendronate therapy, rates of change in BMD at the hip and spine resumed at the background rate, but discontinuation did not result in either accelerated bone loss or a marked increase in bone turnover, showing persistence of alendronate's effects on bone. Data on the effect of continuation versus discontinuation on fracture risk are needed before making definitive recommendations regarding the optimal length of alendronate treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Self-citationEsophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Self-citationPrevention of spinal osteoporosis in oophorectomised women
Lindsay, R., Hart, D. M., Forrest, C., & Baird, C. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92592-1 · Cited by 706
Bone Microdamage and Skeletal Fragility in Osteoporotic and Stress Fractures
Burr, D. B., Forwood, M. R., Fyhrie, D. P., Martin, R. B., Schaffler, M. B., & Turner, C. H. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.6 · Cited by 686
BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY
Christiansen, C., Sanvig Christensen, M., & Transbøl, I. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91848-1 · Cited by 593
Boivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J., & Meunier, P. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00376-8 · Cited by 574
Self-citationMashiba, T., Turner, C. H., Hirano, T., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2001) · Bone · doi:10.1016/s8756-3282(01)00414-8 · Cited by 484
Hochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480
Self-citationJones, G., Nguyen, T., Sambrook, P., Kelly, P. J., & Eisman, J. A. (1994) · BMJ · doi:10.1136/bmj.309.6956.691 · Cited by 451
Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
Alendronate Once-Weekly Study Group, Schnitzer, T., Bone, H. G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., Felsenberg, D., Recker, R. R., Tonino, R. P., et al. (2000) · Aging Clinical and Experimental Research · doi:10.1007/bf03339822 · Cited by 394
Self-citationRoschger, P., Rinnerthaler, S., Yates, J., Rodan, G. A., Fratzl, P., & Klaushofer, K. (2001) · Bone · doi:10.1016/s8756-3282(01)00485-9 · Cited by 384
(1963) · The Lancet · doi:10.1016/s0140-6736(63)90800-6 · Cited by 370
Garnero, P. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.4.1046 · Cited by 362
Ensrud, K. E., Palermo, L., Black, D. M., Cauley, J., Jergas, M., Orwoll, E. S., Nevitt, M. C., Fox, K. M., & Cummings, S. R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101122 · Cited by 358
Self-citationSkeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1
Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6777 · Cited by 335
Self-citationElimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis
Khan, S. A., Kanis, J. A., Vasikaran, S., Kline, W. F., Matuszewski, B. K., McCloskey, E. V., Beneton, M. N. C., Gertz, B. J., Sciberras, D. G., Holland, S. D., et al. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.10.1700 · Cited by 293
Greenspan, S. L., Emkey, R. D., Bone, H. G., Weiss, S. R., Bell, N. H., Downs, R. W., McKeever, C., Miller, S. S., Davidson, M., Bolognese, M. A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00008 · Cited by 223
Self-citationMortensen, L., Charles, P., Bekker, P. J., Digennaro, J., & Johnston, C. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4586 · Cited by 220
Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk?
Faulkner, K. G. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.2.183 · Cited by 205
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women
Tonino, R. P. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3109 · Cited by 188
Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study
Schneider, D. L. (1997) · JAMA · doi:10.1001/jama.277.7.543 · Cited by 187
Design of the Fracture Intervention Trial
Black, D. M., Reiss, T. R., Nevitt, M. C., Cauley, J., Karpf, D., Cummings, S. R., & the Fracture Intervention Trial Research Group (1993) · Osteoporosis International · doi:10.1007/bf01623005 · Cited by 174
Self-citationRosen, H. N., Dresner-Pollak, R., Moses, A. C., Rosenblatt, M., Zeind, A. J., Clemens, J. D., & Greenspan, S. L. (1994) · Calcified Tissue International · doi:10.1007/bf00316285 · Cited by 165
Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis
Miller, P. D., Watts, N. B., Licata, A. A., Harris, S. T., Genant, H. K., Wasnich, R. D., Ross, P. D., Jackson, R. D., Hoseyni, M. S., Schoenfeld, S., et al. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00278-7 · Cited by 153
Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications
Richter, J. E. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00850-3 · Cited by 114
Lafage‐Proust, M., Balena, R., Battle, M. A., Shea, M., Seedor, J. G., Klein, H. J., Hayes, W. C., & Rodan, G. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117901 · Cited by 111
Neele, S. J. M., Evertz, R., Roo, G. W. D. V.-D., Roos, J. C., & Netelenbos, J. C. (2002) · Bone · doi:10.1016/s8756-3282(01)00706-2 · Cited by 108
Mortensen, L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.396 · Cited by 105
Guy, J. A., Shea, M., Peter, C. P., Morrissey, R., & Hayed, W. C. (1993) · Calcified Tissue International · doi:10.1007/bf01320915 · Cited by 97
Landman, J. O., Hamdy, N. A. T., Pauwels, E. K. J., & Papapoulos, S. E. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530584 · Cited by 74
Osteoporosis and Fractures in Postmenopausal Women Using Estrogen
Nelson, H. D., Rizzo, J., Harris, E., Cauley, J., Ensrud, K., Bauer, D. C., & Orwoll, E. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.20.2278 · Cited by 58
Self-citationTiming of Estrogen Replacement Therapy for Optimal Osteoporosis Prevention
Cauley, J. A., Zmuda, J. M., Ensrud, K. E., Bauer, D. C., & Ettinger, B. B. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8079 · Cited by 53
Self-citationLuckey, M. M., Gilchrist, N., Bone, H. G., Davie, M. W., de Villiers, T. J., Wu, M., Daifotis, A. G., Santora, A. C., & Orloff, J. J. (2003) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(03)00008-5 · Cited by 32
Self-citation
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“‘drug holiday’, prospective and retrospective analyses report that the risk of new clinical fractures was 20–40% higher in subjects who stopped treatment [248, 249] and vertebral fracture risk was approximately doubled [226, 250].”
BackgroundBlack, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Self-citationSambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J., Cooper, A., Cooper, C., Gittoes, N., Gregson, C., Harvey, N., Hope, S., Kanis, J. A., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 826
Metadata
- Authors
- Ensrud, K. E., Barrett-Connor, E. L., Schwartz, A., Santora, A. C., Bauer, D. C., Suryawanshi, S., Feldstein, A., Haskell, W. L., Hochberg, M. C., Torner, J. C., Lombardi, A., Black, D. M., & for the Fracture Intervention Trial Long-Term Extension Research Group
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1259-1269
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2001013535
- Cited by
- 275
- References
- 38
- FWCI
- 18.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.